CPD Login
Acne therapy redesigned
An innovative treatment option for acne vulgaris – combining clindamycin (1%) and tretinoin (0.025%), – was launched in South Africa in November.
Are probiotics the panacea to antibiotic-associated diarrhoea?
Several studies have shown that probiotics improve the microbial balance of the host and reduce colonisation by pathogenic bacteria.
Keys to successful diabetes management in Ramadan
Ramadan is observed by Muslims worldwide as a month of fasting, prayer, reflection, and community. In 2022 the Holy month of Ramadan starts on the evening of 2 April, lasting 30 days and ending at sundown on 1 May.1
Novo Nordisk launches once-weekly semaglutide in South Africa
Once-weekly semaglutide, a human glucagon-like peptide 1 receptor agonist (GLP1-RA), was launched in South Africa on 21 August 2021.
Time-saving methods for healthcare professionals
Custom clinical forms save time and effort.
Leveraging reporting to optimise your income
Correctly capturing all clinical and financial information is the key to sound reporting.
Join the fight against antimicrobial resistance
Become an Antibiotic Guardian and do your bit to help safeguard the effectiveness of antibiotics for future generations.
Holiday health hazards
Level one lockdown means South Africans will once again be travelling across the county during the December holidays this year.
4 Festive frustrations
Holidays are supposed to be a time of joy and celebration, but there are several things that can bring spirits down. Fortunately, there are also several things patients can do to treat and prevent them
Probiotics: conducive to life
It is estimated that the probiotic market will surpass the R800bn mark in the United States by 2025.
Metformin: the oldest, but still the best treatment for T2DM
The discovery of metformin began with the synthesis of galegine-like compounds derived from Gallega officinalis; a plant traditionally employed in Europe as a drug for diabetes treatment for centuries
Real-world data from the ARISE Study
The IDegAsp clinical trial program (BOOST) clinical investigation programme for patients with diabetes assessed the safety and efficacy of once or twice daily administration of IDegAsp using 26-week-long treat-to-target studies.
